Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00249964 · ClinicalTrials.gov registry record · Phase 1
Combination Paclitaxel, Carboplatin and Temozolomide
A Phase 1 study of Cancer and Lung Diseases, sponsored by New Mexico Cancer Research Alliance.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT00249964: Completed Phase 1 study of Cancer and Lung Diseases, sponsored by New Mexico Cancer Research Alliance.
NCT00249964 is a Phase 1 study of Cancer and Lung Diseases that has completed, run by New Mexico Cancer Research Alliance. The registered enrollment target is 15 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00249964, a Phase 1 study of Cancer and Lung Diseases, has completed, sponsored by New Mexico Cancer Research Alliance.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the maximum tolerable dose of temozolomide in combination with fixed dose of paclitaxel and carboplatin and to determine the overall tumor response rate with this combination and to determine the duration of response.
Primary Outcome
Temozolomide was administered at different dose levels (see Cohorts 1-4) until the maximum tolerated dose (MTD) was reached. MTD is the dose at which 0/6 or 1/6 patients in the cohort experience dose limiting toxicity (DLT) during the first 4 week cycle with the next higher dose having at least 2/3 or 2/6 patients experiencing DLT. DLT will have occurred when the patient has 1 or more Grade 4 hematologic or nonhematologic toxicities. A DLT must occur in the first cycle of the combination and mus
Conditions Studied
Interventions
- DRUG Combination Treatment - Cohort 1
- DRUG Combination Treatment - Cohort 2
- DRUG Combination Treatment - Cohort 3
- DRUG Combination Treatment - Cohort 4
Study Locations (1)
New Mexico
- University of New Mexico Cancer Center - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2003-11 |
| Est. Completion | 2011-03 |
| Phase | Phase 1 |
What the finished NCT00249964 record still lists
NCT00249964 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 4 interventions - of which Combination Treatment - Cohort 1 is the first listed.
NCT00249964 reports a single indexed study location in New Mexico.
Frequently Asked Questions
What is clinical trial NCT00249964 about?
NCT00249964 is a clinical study titled "Combination Paclitaxel, Carboplatin and Temozolomide". The purpose of this study is to determine the maximum tolerable dose of temozolomide in combination with fixed dose of paclitaxel and carboplatin and to determine the overall tumor response rate with this combination and to determine the duration of response.
What is the current status of trial NCT00249964?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2003-11. Estimated completion is 2011-03.
What conditions does trial NCT00249964 study?
This clinical trial studies the following conditions: Cancer, Lung Diseases.
What interventions are being tested in trial NCT00249964?
The interventions under investigation include: Combination Treatment - Cohort 1 (DRUG), Combination Treatment - Cohort 2 (DRUG), Combination Treatment - Cohort 3 (DRUG), Combination Treatment - Cohort 4 (DRUG).
Who is sponsoring clinical trial NCT00249964?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00249964 being conducted?
This trial has 1 study location across New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00249964's enrollment target sits among peer trials
15 585th of 615 higher than 26 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia